Substance / Medication

Pemigatinib

Overview

Active Ingredient
pemigatinib
RxNorm CUI
2359268
Labeler: Incyte CorporationUpdated: 2025-06-13T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and Toxicity of Pemigatinib in Advanced Cholangiocarcinoma Harboring FGFR Fusions or Rearrangements: A Systematic Review and Meta-analysis.
Akkus Erman, Yasar Hatime Arzu, Rimassa Lorenza et al. · Target Oncol · 2025
PMID: 40223038Meta-Analysis
Precision oncology targeting FGFRs: A systematic review on pre-clinical activity and clinical outcomes of pemigatinib.
Gnagni Ludovica, Ruscito Ilary, Zizzari Ilaria Grazia et al. · Crit Rev Oncol Hematol · 2024
PMID: 39094670Meta-Analysis
Pemigatinib in the Real-World Management of Cholangiocarcinoma Through a Canadian Patient Support Program.
Ding Philip Q, Tam Vincent C, Ramjeesingh Ravi et al. · Curr Oncol · 2025
PMID: 40710216ObservationalFull text (PMC)
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.
Vogel A, Sahai V, Hollebecque A et al. · ESMO Open · 2024
PMID: 38838500ObservationalFull text (PMC)
Remarkable response of gastric adenocarcinoma with FGFR2-TRIM44 fusion to pemigatinib: a case report.
Fujiwara Miho, Ninomiya Kiichiro, Chikuie Emi et al. · Jpn J Clin Oncol · 2026
PMID: 41118275Case Report
Neoadjuvant pemigatinib as a bridge to living donor liver transplantation for intrahepatic cholangiocarcinoma with FGFR2 gene rearrangement.
Byrne Matthew M, Dunne Richard F, Melaragno Jennifer I et al. · Am J Transplant · 2025
PMID: 39515760Case Report
Treating intrahepatic cholangiocarcinoma with pemigatinib: two case reports of Nordic patients.
Väliaho Vesa T, Spanggaard Iben · Acta Oncol · 2025
PMID: 40230323Case ReportFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Pemigatinib (substance)
SNOMED CT
871699001
UMLS CUI
C4724807
RxNorm CUI
2359268
Labeler
Incyte Corporation

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.